CARA: ערך בספרים למניה Cara Therapeutics, Inc.
Supply chain disruption risks for rare components and international patent complexities are impacting Cara Therapeutics, Inc. (CARA), while the GURU.Markets interface displays the book value per share, where 0.88 is the current value of the metric. The humanitarian status of biomedicine guarantees stability, and resilience to crises is ensured by the constant demand for renal pruritus therapy.
פילוחי נתונים אנליטיים מרוכזים עבור caratherapeutics.com (CARA)
Professional issuer selection is based on comparing the market price with the actual net asset value per share. Book value per share data reflects the actual capital of Cara Therapeutics, Inc. (CARA), which is critical for assessing the biotech's resilience to geopolitical risks and rare component supply chain disruptions, allowing investors to promptly identify overvalued or distressed assets.